Patents for A61P 35 - Antineoplastic agents (221,099)
02/2007
02/15/2007WO2007018272A1 Sugar-modified liposome and composition for drug delivery containing the liposome
02/15/2007WO2007018248A1 Pyridone compound
02/15/2007WO2007018229A1 Treatment of adult t-cell leukemia
02/15/2007WO2007018199A1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hal-a2-positive patient and pharmaceutical comprising the antigen
02/15/2007WO2007018198A1 Cancer-rejection antigen peptide derived from hsp105 for use in hal-a2-positive patient and pharmaceutical comprising the antigen
02/15/2007WO2007018147A1 Pharmaceutical titanium dioxide composite material of which pharmacological effect can be eliminated by light irradiation
02/15/2007WO2007018143A1 Use of gene which varies in amount of expression during the course of transition from precancer to cancer
02/15/2007WO2007018137A1 Multikinase inhibitor
02/15/2007WO2007018049A1 Antigen capable of inducing neutralizing antibody for high risk-type human papillomavirus
02/15/2007WO2007018047A1 Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule
02/15/2007WO2007017740A1 Salts and polymorphs of a vergf-r inhibitor
02/15/2007WO2007017678A1 Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
02/15/2007WO2007017643A1 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION
02/15/2007WO2007017585A2 Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
02/15/2007WO2007017577A1 7-substituted aza-indazoles, compositions containing same, production method and use thereof
02/15/2007WO2007017507A1 Beta-secretase inhibitors for use in the treatment of alzheimer's disease
02/15/2007WO2007017222A1 Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
02/15/2007WO2007017212A2 Use of an active biological substance in abnormal cellular and viral membrane physiologies
02/15/2007WO2007017169A1 Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
02/15/2007WO2007017143A1 Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
02/15/2007WO2007017139A1 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
02/15/2007WO2007017083A1 Pyrazole derivatives having tyrosinkinase activity
02/15/2007WO2007017069A1 Adenine derivatives
02/15/2007WO2007016979A2 NOVEL HETEROCYCLIC NF-κB INHIBITORS
02/15/2007WO2007016954A1 Composition for reducing drug or alcohol induced breast cancer risk
02/15/2007WO2007016777A1 Targeted protein kinase c inhibitors and uses thereof
02/15/2007WO2006136837A3 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
02/15/2007WO2006123122A3 Psk- i and its modulators for the treatment/diagnosis of cancer
02/15/2007WO2006099095A3 Ribosome inhibitors as inhibitors of tyrosyl-dna-phosphodiesterase
02/15/2007WO2006082304A3 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof
02/15/2007WO2006081337A3 Erastin analogues and their uses for killing cancer cells
02/15/2007WO2006078752A3 Inhibitors of dna methyltransferase
02/15/2007WO2006067614B1 Heteroaromatic derivatives useful as anticancer agents
02/15/2007WO2006020060A3 Iap binding compounds
02/15/2007WO2005110487A3 Camptothecin derivatives conjugated in position 20 with integrin antagonists
02/15/2007US20070037996 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants
02/15/2007US20070037995 A Substantially Cell Membrane Impermeable Compound And Use Thereof
02/15/2007US20070037967 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer
02/15/2007US20070037883 Therapeutic compositions
02/15/2007US20070037879 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
02/15/2007US20070037878 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
02/15/2007US20070037864 Intermediates for the preparation of lipoxin A4 analogs
02/15/2007US20070037856 Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease
02/15/2007US20070037852 Migrastatin analogs and uses thereof
02/15/2007US20070037837 Quinazoline derivatives
02/15/2007US20070037834 Bicyclic pyrimidine derivatives
02/15/2007US20070037832 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis
02/15/2007US20070037826 Indolylmaleimide derivatives
02/15/2007US20070037825 Enhancing the effect of radioimmunotherapy in the treatment of tumors
02/15/2007US20070037803 Benzimidazole derivatives
02/15/2007US20070037774 Novel cytarabine monophosphate prodrugs
02/15/2007US20070037770 Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
02/15/2007US20070037750 Exendin agonist composed of a peptide in which at least one amino acid residue is acylated with a dicarboxylic acid; the amino acid residues are an internal lysine residue, an N-terminal amino acid residue, and/or a C-terminal amino acid residue; treatment of glucagonoma
02/15/2007US20070037738 Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions
02/15/2007US20070037159 Tetrahydrofolate synthetase gene
02/15/2007US20070037147 Endogenous retrovirus polypeptides linked to oncogenic transformation
02/15/2007US20070037145 drug screening; for carcinomas, especially lymphoma carcinomas
02/15/2007US20070037136 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents
02/15/2007US20070036854 Therapeutic applications of pro-apoptotic benzodiazepines
02/15/2007US20070036812 polypeptide with binding to antigen and is recognized by cytotoxic T lymphocytes; use as cancer vaccine
02/15/2007US20070036808 Cancer antigen peptide formulations
02/15/2007US20070036798 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
02/15/2007US20070036790 Treatment with anti-vegf antibodies
02/15/2007US20070036785 Pharmaceutical composition for treatment of diseases caused by IL-6 production
02/15/2007US20070036780 Modified proteins, designer toxins, and methods of making thereof
02/15/2007US20070036774 Liver engrafting cells, assays, and uses thereof
02/15/2007US20070036759 Method of preparing a proliferation-regulated recombinant adenoviral vector efficiently and kit for preparing the same
02/15/2007US20070036754 Treatment with anti-vegf antibodies
02/15/2007US20070036753 Treatment with anti-vegf antibodies
02/15/2007US20070036752 IL-2 fusion proteins with modulated selectivity
02/15/2007US20070036751 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
02/15/2007US20070036720 Radiolabelled metal transport protein as imaging agent
02/15/2007US20070036714 Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy
02/15/2007DE202006017823U1 Dietic food with increased effect of free radical binder, useful, e.g. for the treatment of allergic condition disease, comprises a protein and a sugar
02/15/2007DE102005038347A1 Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung Producing an oxaliplatin solution and container and container set with the solution
02/15/2007DE102005037733A1 Adeninderivate Adenine derivatives
02/15/2007DE102005037499A1 Pyrazolderivate Pyrazole derivatives
02/15/2007DE102005036656A1 Pharmaceutical composition containing IKK-beta inhibitor and agent for treating inflammation or tumor of the skin, useful for topical treatment of e.g. inflamed skin and tumors of the eye
02/15/2007CA2820233A1 Perylenequinone derivatives and uses thereof
02/15/2007CA2659961A1 Targeted protein kinase c inhibitors and uses thereof
02/15/2007CA2620952A1 3, 11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
02/15/2007CA2619443A1 Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same
02/15/2007CA2618765A1 Methods for treating b-cell malignancies using taci-ig fusion molecule
02/15/2007CA2618763A1 Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
02/15/2007CA2618657A1 Method for evaluating compound using molecule on the rb pathway as index and molecular diagnostic method
02/15/2007CA2618633A1 Adenine derivatives
02/15/2007CA2618542A1 Prophylactic/therapeutic agent for cancer
02/15/2007CA2618524A1 Pyrazole derivatives having tyrosine kinase activity
02/15/2007CA2618370A1 Oxazolopyridine derivatives as sirtuin modulators
02/15/2007CA2618360A1 Benzothiazoles and thiazolopyridines as sirtuin modulators
02/15/2007CA2618112A1 Pyridone compound
02/15/2007CA2618069A1 Dihydroxyanthraquinones and their use
02/15/2007CA2618013A1 Beta-secretase inhibitors for use in the treatment of alzheimer's disease
02/15/2007CA2617557A1 Benzimidazole derivatives as sirtuin modulators
02/15/2007CA2617293A1 7-substituted aza-indazoles, compositions containing same, production method and use thereof
02/15/2007CA2617274A1 Use of hdac inhibitors for the treatment of myeloma
02/15/2007CA2617225A1 Novel heterocyclic nf-kb inhibitors
02/15/2007CA2616075A1 Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
02/15/2007CA2615760A1 Salts and polymorphs of n,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide
02/15/2007CA2615695A1 Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents